

1 **Title:** A Third Dose of SARS-CoV-2 Vaccine Increases Neutralizing Antibodies Against  
2 Variants of Concern in Solid Organ Transplant Recipients

3 **Authors:** Andrew H. Karaba<sup>1</sup>, Xianming Zhu<sup>2</sup>, Tao Liang<sup>1</sup>, Kristy H. Wang<sup>1</sup>, Alex G.  
4 Rittenhouse<sup>1</sup>, Olivia Akinde<sup>2</sup>, Yolanda Eby<sup>2</sup>, Joel N. Blankson<sup>1</sup>, Aura Teles<sup>3</sup>, Jennifer L.  
5 Alejo<sup>3</sup>, Andrea L. Cox<sup>1,4,5</sup>, Justin R. Bailey<sup>1</sup>, Sabra L. Klein<sup>1,4</sup>, Andrew Pekosz<sup>1,4</sup>,  
6 Jacqueline M. Garonzik-Wang<sup>3</sup>, Brian J. Boyarsky<sup>3</sup>, Dorry L. Segev<sup>3</sup>, Aaron A.R.  
7 Tobian<sup>2</sup>, William A. Werbel<sup>1</sup>

8 **Author Affiliations:**

9 <sup>1</sup>Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.  
10 <sup>2</sup>Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA  
11 <sup>3</sup>Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.  
12 <sup>4</sup>W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University  
13 Bloomberg School of Public Health, Baltimore, MD 21287, USA  
14 <sup>5</sup>Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine,  
15 Baltimore, MD 21287, USA.  
16

17 **Abstract:** Immunocompromised populations are at high risk for severe COVID-19.  
18 Vaccine-induced SARS-CoV-2 antibody responses are attenuated in solid organ  
19 transplant recipients (SOTRs), and breakthrough infections are more common.  
20 Additional SARS-CoV-2 vaccine doses may increase anti-spike antibody titers in some  
21 SOTRs, but whether this results in enhanced neutralizing capability, especially versus  
22 novel variants of concern (VOCs) that exhibit immune escape and higher infectivity  
23 (e.g., the Delta variant), is unclear. Here, we report that a third dose of a SARS-CoV-2  
24 vaccine increases anti-SARS-CoV-2 spike and RBD IgG levels as well as plasma  
25 neutralizing capability versus VOCs, including Delta, in some SOTRs. However, anti-  
26 spike IgG and neutralizing capability remained significantly reduced compared to fully  
27 vaccinated healthy controls. These findings highlight the need for continued study of

28 strategies to improve protection from COVID-19 in immunosuppressed populations as  
29 more SARS-CoV-2 VOCs emerge.

30 **Main Text:** Solid organ transplant recipients (SOTRs) are at increased risk for severe  
31 COVID-19<sup>1</sup>. For example, case fatality ratios range from 10-30% in SOTRs, due to a  
32 combination of chronic disease and immunosuppressive medications<sup>2</sup>. Therefore,  
33 effective and optimized vaccines that prevent COVID-19 disease in this group are  
34 critical. Unfortunately, these patients were excluded from the Phase III trials of the  
35 mRNA based COVID-19 vaccines,<sup>3,4</sup> and recent publications suggest that breakthrough  
36 infections are more common among fully-vaccinated SOTRs than the general  
37 population<sup>5,6</sup>. Furthermore, it has been demonstrated that many SOTRs develop weak  
38 SARS-CoV-2 antibody responses after the recommended two doses of an mRNA-  
39 based vaccine<sup>7-10</sup>. This led to the hypothesis that a third dose of SARS-CoV-2 vaccine  
40 may improve the immune response and protection from COVID-19. While the number of  
41 SOTRs receiving a third dose remains small, preliminary data suggest that a subset of  
42 non-responders do mount higher antibody responses<sup>11,12</sup>. It is unclear, however, if this  
43 response will be protective, particularly against more transmissible variants of concern  
44 (VOCs) that exhibit immune escape, including the Delta variant which comprises >80%  
45 of new cases in the USA<sup>13-15</sup>.

46 In an effort to assess whether a third dose of SARS-CoV-2 vaccine in SOTRs  
47 would improve the SARS-CoV-2 specific neutralizing response, we measured total  
48 SARS-CoV-2 specific IgG and neutralizing antibodies against the previously dominant  
49 D614G strain and four VOCs before and after a third dose of SARS-CoV-2 vaccine, and

50 compared this to IgG levels and neutralizing capacity of healthy controls who received a  
51 standard two-dose mRNA-based vaccine series.

52 Pre- and post-third dose samples were available for 31 SOTRs who were  
53 followed in our ongoing longitudinal observational cohort studying immunogenicity and  
54 safety of SARS-CoV-2 vaccination. Most of these participants had previously undergone  
55 anti-spike antibody testing using two clinically available assays<sup>11</sup>. The median age was  
56 60 (interquartile range 49-67) years and 55% were female. Most SOTRs were kidney  
57 transplant recipients (61%) and all initially received two doses of an mRNA-based  
58 vaccine. Most were taking a calcineurin inhibitor-based maintenance  
59 immunosuppression regimen (81%). Among mRNA-vaccinated healthy controls (N=15),  
60 none had known medical conditions, and all received two doses of an mRNA-based  
61 vaccine. See **Supplemental Table 1** for full demographic and clinical data.

62 We measured anti-S1-RBD (RBD), anti-Spike (S), and anti-Nucleocapsid (N)  
63 total IgG in plasma using a research assay (Meso Scale Diagnostics) with FDA verified  
64 cutoffs for sero-positivity before and after a third dose of SARS-CoV-2 vaccine in  
65 SOTRs and healthy controls after two doses of an mRNA-based vaccine. No  
66 participants had a positive anti-N response at baseline (**Supplemental Figure 1**). Prior  
67 to a third dose of vaccine 12 (39%) and 8 (26%) SOTRs were positive for anti-RBD and  
68 anti-S respectively (**Figure 1A**). After the third dose, these numbers increased to 24  
69 (77%), and 22 (71%) respectively and there was a significant increase in the median of  
70 total anti-S and anti-RBD IgG compared to matched pre-third dose samples (**Figure**  
71 **1A**). The median of anti-RBD and anti-S IgG values of SOTRs receiving a third dose  
72 remained significantly lower than the median responses in fully vaccinated healthy

73 controls after the two-dose series (**Figure 1B**). When stratifying by type of third dose  
74 received (Ad26.COVS2.S [n=12] or mRNA-based [n=19]), we observed a trend toward a  
75 greater increase in the median anti-S IgG value among those receiving a third mRNA-  
76 based vaccine dose, though this did not reach statistical significance (**Figure 1C**). Six  
77 (50%) of those receiving the Ad26.COVS2.S as a third dose and 16 (84%) who received  
78 an mRNA-based vaccine as a third dose became sero-positive. In exploratory analysis,  
79 median IgG levels did not differ by key clinical or demographic parameters such as age,  
80 sex, or type of organ transplant, though subgroup sizes were small (**Supplemental**  
81 **Figure 2**).

82       Next, we investigated the neutralizing potential of SOTR plasma versus major  
83 SARS-CoV-2 VOCs after three vaccine doses with comparison to that of healthy  
84 individuals after two vaccine doses. There was a significant increase in the median  
85 pseudoneutralization (inhibition of S protein binding to the ACE2 receptor) of all variants  
86 after a third vaccine dose among SOTRs (**Figure 2A**). However, pseudoneutralization  
87 of all variants was significantly lower than that of healthy controls after two doses of an  
88 mRNA-based vaccine (**Figure 2B**). For example, only two (6%) SOTRs had  
89 pseudoneutralization values for the Delta variant above the first quartile of the healthy  
90 control pseudoneutralization values; the majority were below 25% inhibition for all  
91 variants. When stratified by type of third dose received, SOTRs receiving a third dose of  
92 an mRNA-based vaccine had greater pseudoneutralization than those receiving the  
93 adenovirus-based vaccine, but the difference did not reach statistical significance  
94 (**Figure 2C**). Stratification by age, sex, or type of graft received did not identify any  
95 significant differences in pseudoneutralization (**Supplemental Figure 3**). Finally, we

96 examined the correlation between anti-S IgG and pseudoneutralization for all the  
97 variants. We found a strong correlation between anti-S IgG and pseudoneutralization,  
98 but the relationship only became linear at approximately a value of  $4 \log_{10}(\text{AU})$  IgG,  
99 suggesting that values below this may not correlate with neutralizing response (**Figure**  
100 **2D**).

101 Here, we provide the first evidence that a third dose of COVID-19 vaccine in  
102 SOTRs may increase neutralization against VOCs, including the highly transmissible  
103 and now dominant Delta variant. Further, our results are consistent with recent reports  
104 suggesting that a third dose of SARS-CoV-2 vaccine in SOTRs who fail to mount a  
105 positive antibody response to two doses of mRNA vaccine may increase the humoral  
106 immune response to SARS-CoV-2 based on measurement of IgG antibodies<sup>12,16,17</sup>.  
107 Additionally, pseudoneutralization capacity did increase after a third vaccine dose,  
108 which may indicate improved protection against COVID-19. However, the majority of  
109 SOTRs still did not demonstrate high-level ACE2 binding inhibition as was seen in  
110 nearly all healthy controls receiving the currently recommended two dose series. This  
111 was particularly true of the Gamma variant, known to cause vaccine breakthrough<sup>18</sup>. It is  
112 not yet certain whether this correlates with decreased protection from severe disease.  
113 We also found a trend on exploratory analysis of greater total IgG and  
114 pseudoneutralization with a third dose of an mRNA-based vaccine than with an  
115 adenovirus-based vaccine. This is consistent with prior work demonstrating somewhat  
116 lower humoral response to the one and two-dose Ad26.COVS.S series as compared to  
117 the two-dose mRNA series; a study in SOTRs also noted lower antibody levels after one  
118 dose of Ad26.COVS.s<sup>19,20</sup>. Regardless, a mixed-platform dosing strategy is of interest

119 given a recent study of healthy individuals who received an initial dose of an  
120 adenovirus-based vaccine demonstrated that an mRNA-based vaccine booster led to  
121 superior SARS-CoV-2 specific antibody production when compared to homologous  
122 adenovirus-based vaccine, leading to the hypothesis that a cross-platform approach  
123 may be an effective strategy for boosting the humoral response to the virus<sup>21</sup>. However,  
124 our preliminary data found higher anti-S IgG as well as pseudoneutralization with  
125 homologous mRNA boosting, which may suggest that the sequence (i.e., adenovirus  
126 followed by mRNA, instead of mRNA followed by adenovirus) may be important when  
127 considering an additional dose of vaccine in the SOTR population.

128         Although these data suggest that additional immunizations may increase  
129 protection from SARS-CoV-2 VOCs in vulnerable SOTRs, increases in antibody titers  
130 and pseudoneutralization were not observed in every SOTR. This suggests that  
131 additional strategies, such as immunosuppressive modulation or utilization of emerging  
132 vaccine platforms, may be necessary to induce a protective response to vaccination in  
133 SOTRs. Additional investigations are warranted to understand why some SOTRs  
134 respond to additional antigen exposure, while others do not.

135         This study was limited by its observational nature and small number of  
136 participants. Furthermore, while the pseudoneutralization assay employed correlates  
137 well with live-virus neutralization<sup>22</sup>, it is possible that this assay either under or over  
138 estimates the true neutralization capacity of plasma. Despite these limitations, these  
139 results provide important and timely information regarding the potential to improve  
140 protection from SARS-CoV-2 variants in a highly vulnerable population amidst ongoing  
141 community surges.

142 **Methods (online):**

143 *Cohorts:*

144 SOTR participants were enrolled in a national prospective, observational cohort:  
145 COVID-19 Antibody Testing of Recipients of Solid Organ Transplants and Patients with  
146 Chronic Diseases, Johns Hopkins IRB00248540, as previously described<sup>8,11</sup>. SOTRs  
147 submitted blood samples to the investigators 0-4 weeks before and 2 weeks after third  
148 vaccine doses, which were independently obtained in the community. Healthy control  
149 participants were enrolled under Johns Hopkins IRB00027183. Blood was collected in  
150 Acid Citrate Dextrose (ACD) tubes and plasma was isolated by Ficoll centrifugation and  
151 stored at -80°C.

152 *IgG Measurement:*

153 Plasma was thawed and anti-N, anti-RBD, and anti-S IgG was measured using  
154 the multiplex chemiluminescent Meso Scale Diagnostics (MSD) V-PLEX COVID-19  
155 Respiratory Panel 3 Kit according to the manufactures' protocol at a dilution of 1:5000.  
156 Two participants in the original SOTR cohort had N IgG values that rose above the  
157 cutoff after a third dose suggesting possible exposure to SARS-CoV-2 (**Supplemental**  
158 **Figure 1**), and they were subsequently excluded from analysis.

159 *Pseudoneutralization/ACE2 Inhibition Measurement:*

160 Plasma from study participants was thawed and ACE2 blocking was measured  
161 using the ACE2 MSD V-PLEX SARS-CoV-2 Panel 6 and Panel 14 kits according to the  
162 manufacturers' protocol at a dilution of 1:100.

163 *Statistical analysis:*

164           Only SOTRs with available demographic and immunological data on pre and  
165 post third dose of SARS-Cov-2 vaccine were included in the analysis. Wilcoxon signed  
166 rank test was used to compare the median of SARS-Cov-2 anti-Spike and anti-RBD IgG  
167 level and percent ACE2 inhibition before and after third dose of vaccine among SOTRs.  
168 The median of IgG level and ACE2 inhibition between SOTRs and HCs were compared  
169 using Wilcoxon rank sum test. Pearson correlation were used to evaluate the linear  
170 association between Spike IgG and percent ACE2 inhibition among SOTRs. A spline  
171 knot was added at  $4 \log_{10}(\text{AU})$  IgG. Bonferroni correction was conducted to control  
172 multiple comparison when analyzing variants ( $p < 0.01$  was considered statistically  
173 significant). The analysis was also stratified by type of third dose vaccine, age, sex, and  
174 graft transplanted to evaluate effect measure modification. Missing values were treated  
175 using available case strategy in subgroup analysis.

#### 176 **Acknowledgements:**

177           This work was supported by the Ben-Dov family, the Johns Hopkins COVID-19  
178 Vaccine-related Research Fund, the National Cancer Institute (U54CA260491), grants  
179 5T32DK007713 (JLA), F32DK124941 (BJB), and K23DK115908 (JMGW) from the  
180 National Institute of Diabetes and Digestive and Kidney Diseases, and grants  
181 K24AI144954 (DLS), K08AI156021 (AHK), and R01AI120938S1 (AART) from the  
182 National Institute of Allergy and Infectious Disease.

#### 183 **Author contributions:**

184 AHK and WAW conceived of the study and design. OA and YE processed the samples  
185 and prepared them for the assays. AHK, KHW, and AGR performed the assays and  
186 collected the antibody data. AT, JLA, JNB, and BJB assisted with participant enrollment



187 and collection of clinical data. XZ and TL performed the analysis. AHK wrote the original  
188 manuscript. JMG, ALC, JNB, SLK, AP, JRB, DLS, AART, and WAW supervised the  
189 studies, provided material support, and contributed to the interpretation of results. All  
190 authors aided in editing the manuscript.

191

192 **Competing Interests:** DLS has the following financial disclosures: consulting and  
193 speaking honoraria from Sanofi, Novartis, CSL Behring, Jazz Pharmaceuticals, Veloxis,  
194 Mallinckrodt, Thermo Fisher Scientific. None of the other authors have any relevant  
195 competing interests.

196

197

198

## 199 **FIGURE LEGENDS**


200 **Figure 1. Changes in SARS-CoV-2 Specific IgG After A Third Dose of SARS-CoV-2**  
201 **Vaccine**

202

203 **a.** Total SARS-CoV-2 S1 RBD (left) and Spike (right) specific IgG in SOTRs before  
204 and after a third dose of vaccine. The dashed line represents the assay  
205 manufacturer's cut-off for positivity based on convalescent samples.

206 **b.** Total SARS-CoV-2 S1 RBD (left) and Spike (right) specific IgG in fully mRNA  
207 vaccinated healthy controls (HCs) (n = 15) and SOTRs after a third dose of  
208 vaccine (n = 31).

209 **c.** Total SARS-CoV-2 Spike specific IgG in SOTRs who received a third dose  
210 consisting of either Ad26.COVID.S (n = 12) or mRNA-based vaccine (n = 19).  
211  
212 The boxplots represent the IQR. The median is represented by a horizontal line in  
213 the box. The lower and upper whiskers represent 1.5x the IQR beyond the quartiles.  
214 Each dot represents an individual sample. Statistical differences between groups  
215 were determined by Wilcoxon signed rank test for panel A, and Wilcoxon rank sum  
216 test for panel B and C. P-values of 0.05 were considered significant.  
217



218 **Figure 2. SARS-CoV-2 Pseudoneutralization After A Third Dose of COVID-19**

219 **Vaccine in SOTRs**

220


221 **a.** Pseudoneutralization of full-length SARS-CoV-2 Spike variants (indicated in top  
222 header of each panel) before and after a third dose of COVID-19 vaccine among  
223 SOTRs.

224 **b.** Pseudoneutralization of full-length SARS-CoV-2 Spike variants (indicated in top  
225 header of each panel) in SOTRs (n = 31) after a third dose of vaccine compared  
226 to fully vaccinated healthy controls (n = 15).

227 **c.** Comparison of pseudoneutralization of full-length SARS-CoV-2 Spike variants  
228 (indicated in top header of each panel) between SOTRs receiving a third dose of  
229 Ad26.COVS (n = 12) or mRNA-based vaccine (n = 19).

230 **d.** Correlation between total SARS-CoV-2 Spike IgG and pseudoneutralization of  
231 full-length SARS-CoV-2 Spike variants among SOTRs receiving a third dose of  
232 COVID-19 vaccine.

233 In panel A-C, the boxplots represent the IQR. The median is represented by a  
234 horizontal line in the box. The lower and upper whiskers represent 1.5x the IQR  
235 beyond the quartiles. Each dot represents an individual sample. Statistical  
236 differences between groups were determined by Wilcoxon signed rank test for panel  
237 A, and Wilcoxon rank sum test for panel B and C. Pearson correlation coefficient  
238 were generated for panel D. P-values of 0.01 were considered significant after  
239 Bonferroni correction.



240  
241

242 **Supplemental Table 1. Clinical and Demographic Characteristics of SOTRs and**  
 243 **Healthy Controls.**

	<b>Overall n = 46</b>	<b>SOTR n = 31</b>	<b>Healthy controls, n = 15</b>
Age, years			
20-39	9 (20)	2 (7)	7 (47)
40-59	21 (46)	13 (42)	8 (53)
60-79	16 (35)	16 (52)	0 (0)
Sex			
Female	22 (48)	17 (55)	5 (33)
Male	21 (46)	11 (36)	10 (67)
Missing	3 (7)	3 (10)	0 (0)
Race			
White	39 (85)	28 (90)	11 (73)
Asian	3 (7)	0 (0)	3 (20)
African American	1 (2)	0 (0)	1 (7)
Missing	3 (7)	3 (10)	0 (0)
Graft transplanted			
Kidney	-	19 (61)	-
Other*	-	12 (39)	-
Anti-rejection medication†			
Prednisone	-	16 (52)	-
Calcineurin Inhibitors	-	25 (81)	-
mTOR inhibitors	-	3 (10)	-
anti-metabolites	-	20 (65)	-
Type of the third dose vaccine			
mRNA	-	19 (61)	-
Ad26.COV2.S	-	12 (39)	-
Days between second dose and third dose vaccine	-	83 (62 – 105)	-
Days between transplant and third dose vaccine	-	1778 (844 – 3954)	-
Days post second dose vaccine	-	-	8 (7 – 10)

244 Note: all study participants received mRNA vaccine for the first two doses. Categorical variables were presented in  
 245 n (%), and continuous variables were presented in median (interquartile range). Other transplanted grafts includes ,  
 246 liver (n = 7), heart (n = 3), pancreas (n = 1) and lung (n = 1). 1 person had both kidney and pancreas transplanted  
 247 and has been grouped into kidney category. †Anti-rejection medication use was not mutually exclusive.

248


249

250

251

252 **Supplemental Figure 1.**

253 Total SARS-CoV-2 Nucleocapsid specific IgG in SOTRs before and after a third dose of  
254 vaccine. The dashed line represents the assay manufacturer's cut-off for positivity  
255 based on convalescent samples. P values were calculated using Wilcoxon rank sum  
256 test.






257

258

259 **Supplemental Figure 2.**

260 Total SARS-CoV-2 Spike specific IgG in SOTRs who received a third dose of COVID-19  
261 vaccine stratified by age (<60 n = 15 and ≥60 years n = 16), sex (Female n = 17 and  
262 male n = 11), and graft received (Kidney n = 19 and other n = 12). P values were  
263 calculated using Wilcoxon rank sum test and should be considered exploratory given  
264 the small subgroups.






265





267 **Supplemental Figure 3.**

268 Pseudoneutralization of full-length SARS-CoV-2 Spike variants in SOTRs who received  
269 a third dose of COVID-19 vaccine stratified by age (<60 n = 15 and ≥60 years n = 16),  
270 sex (Female n = 17 and male n = 11), and graft received (Kidney n = 19 and other n =  
271 12). P values were calculated using Wilcoxon rank sum test and should be considered  
272 exploratory given the small subgroups.



273

274

## 275 REFERENCES



276 1. Fung, M. & Babik, J. M. COVID-19 in Immunocompromised Hosts: What We Know

277 So Far. *Clinical Infectious Diseases* **72**, 340–350 (2021).


- 278 2. Raja, M. A. *et al.* COVID-19 in solid organ transplant recipients: A systematic review  
279 and meta-analysis of current literature. *Transplantation Reviews* **35**, 100588 (2021).
- 280 3. Baden, L. R. *et al.* Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.  
281 *New England Journal of Medicine* **384**, 403–416 (2021).
- 282 4. Polack, F. P. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.  
283 *New England Journal of Medicine* **383**, 2603–2615 (2020).
- 284 5. Aslam, S., Adler, E., Mekeel, K. & Little, S. J. Clinical effectiveness of COVID-19  
285 vaccination in solid organ transplant recipients. *Transplant Infectious Disease* **n/a**,  
286 e13705 (2021).
- 287 6. Qin, C. X. *et al.* Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant  
288 Recipients. *Transplantation* (2021) doi:10.1097/TP.0000000000003907.
- 289 7. Boyarsky, B. J. *et al.* Immunogenicity of a Single Dose of SARS-CoV-2 Messenger  
290 RNA Vaccine in Solid Organ Transplant Recipients. *JAMA* **325**, 1784–1786 (2021).
- 291 8. Boyarsky, B. J. *et al.* Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine  
292 Series in Solid Organ Transplant Recipients. *JAMA* **325**, 2204–2206 (2021).
- 293 9. Hall, V. G. *et al.* Humoral and cellular immune response and safety of two-dose  
294 SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients. *American*  
295 *Journal of Transplantation* **n/a**, (2021).
- 296 10. Sattler, A. *et al.* Impaired humoral and cellular immunity after SARS-CoV2  
297 BNT162b2 (Tozinameran) prime-boost vaccination in kidney transplant recipients. *J*  
298 *Clin Invest* (2021) doi:10.1172/JCI150175.

- 299 11. Werbel, W. A. *et al.* Safety and Immunogenicity of a Third Dose of SARS-CoV-2  
300 Vaccine in Solid Organ Transplant Recipients: A Case Series. *Ann Intern Med* (2021)  
301 doi:10.7326/L21-0282.
- 302 12. Kamar, N. *et al.* Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ  
303 Transplant Recipients. *New England Journal of Medicine* **0**, null (2021).
- 304 13. Dougherty, K. SARS-CoV-2 B.1.617.2 (Delta) Variant COVID-19 Outbreak  
305 Associated with a Gymnastics Facility — Oklahoma, April–May 2021. *MMWR Morb*  
306 *Mortal Wkly Rep* **70**, (2021).
- 307 14. Walensky, R. P., Walke, H. T. & Fauci, A. S. SARS-CoV-2 Variants of Concern in  
308 the United States—Challenges and Opportunities. *JAMA* **325**, 1037–1038 (2021).
- 309 15. CDC. COVID Data Tracker. *Centers for Disease Control and Prevention*  
310 <https://covid.cdc.gov/covid-data-tracker> (2020).
- 311 16. Del Bello, A. *et al.* Efficiency of a boost with a third dose of anti–SARS-CoV-2  
312 messenger RNA–based vaccines in solid organ transplant recipients. *American*  
313 *Journal of Transplantation* **n/a**, (2021).
- 314 17. Benotmane, I. *et al.* Antibody Response After a Third Dose of the mRNA-1273  
315 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic  
316 Response to 2 Doses. *JAMA* (2021) doi:10.1001/jama.2021.12339.
- 317 18. Vignier, N. *et al.* Breakthrough Infections of SARS-CoV-2 Gamma Variant in Fully  
318 Vaccinated Gold Miners, French Guiana, 2021. *Emerging Infectious Diseases* (2021)  
319 doi:<https://doi.org/10.3201/eid2710.211427>.
- 320 19. Boyarsky, B. J. *et al.* Antibody Response to the Janssen COVID-19 Vaccine in  
321 Solid Organ Transplant Recipients. *Transplantation* **105**, (2021).




- 322 20. Stephenson, K. E. *et al.* Immunogenicity of the Ad26.COV2.S Vaccine for  
323 COVID-19. *JAMA* **325**, 1535–1544 (2021).
- 324 21. Barros-Martins, J. *et al.* Immune responses against SARS-CoV-2 variants after  
325 heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. *Nat Med*  
326 1–5 (2021) doi:10.1038/s41591-021-01449-9.
- 327 22. Amjadi, M. F. *et al.* Fever, Diarrhea, and Severe Disease Correlate with High  
328 Persistent Antibody Levels against SARS-CoV-2. *medRxiv* 2021.01.05.21249240  
329 (2021) doi:10.1101/2021.01.05.21249240.
- 330



Cohort ● HCs ● SOTR



Third Dose Vaccine ● Ad26.COVS2.S ● mRNA

**a****b****c****d**